A Phase 2 interventional study of Gepotidacin in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-29.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gepotidacin in Bacterial Infections — 1 open to participants now, 1 under way, none of them phase 3. gepotidacin · Bacterial Infections.
Among the 11 studies testing gepotidacin in Bacterial Infections, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 2, and was the 7th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 11 studies testing gepotidacin in Bacterial Infections is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2018.
This study's enrollment of 22 is below the median of 84 across 382 interventional studies indexed under Bacterial Infections.
Median enrollment 34 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Bacterial Infections by GlaxoSmithKline: 1 open now, 1 under way, none of them phase 3. Of 29 finished, 13 (45%) have results posted.
Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 24th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2018, is one of 4 in phase 2, and was the 31st registered.
GlaxoSmithKline’s Bacterial Infections studies by the year they started, since 2005.
1 of the studies testing gepotidacin in Bacterial Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing gepotidacin in Bacterial Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Bacterial Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor that is being developed for the treatment of uncomplicated urinary tract infections (UTIs; acute cystitis). This Phase IIa study will evaluate plasma and urine pharmacokinetics of gepotidacin in female subjects with acute cystitis. Eligible female subjects will receive twice daily (BID) dose of gepotidacin 1500 milligram (mg) for 5 days via oral route. Pre-treatment and post-treatment samples for pharmacokinetic (PK) assessments will be collected throughout the study. The total duration of the study is approximately 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (\>=10 WBC/mm\^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
Drug: Gepotidacin
Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
Area Under the Plasma Concentration-time Curve (AUC) From Zero (Pre-dose) Over the Dosing Interval (AUC[0-tau]) of Gepotidacin
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. PK Parameter Population consisted of all participants who received gepotidacin 1500 mg BID through the completion of all PK collections for whom valid and evaluable plasma PK parameters were derived for gepotidacin.
Time frame: Days 1 and 4: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Maximum Plasma Concentration (Cmax) of Gepotidacin
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 and 4: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Time of Occurrence of Cmax (Tmax) of Gepotidacin
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 and 4: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Apparent Steady State Clearance (CLss/F) of Gepotidacin
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. CLss/F was calculated as Dose divided by AUC(0-tau).
Time frame: Day 4: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Accumulation Ratio (Ro) of Gepotidacin
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Accumulation ratio (Ro) was calculated as ratio of AUC(0-tau) at Day 4 to AUC(0-tau) at Day 1.
Time frame: Days 1 and 4: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours post-dose
Plasma Pre-dose Concentration (Ctau) of Gepotidacin
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 to 5: Pre-dose
Amount of Drug Excreted Over 12 Hours (Ae12hours) of Gepotidacin
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Ae12hours was calculated by adding all the fractions of drug collected over all the allotted time intervals.
Time frame: Days 1 and 4: Pre-dose and at 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, and 10 to 12 hours post-dose
Amount of Drug Excreted in Urine in a Time Interval (Ae[t1-t2]) of Gepotidacin
Ae(t1-t2) measure the amount of drug excreted in urine in a time intervals 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, and 10 to 12 hours post-dose on Days 1 and 4. The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 and 4: Pre-dose and at 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, and 10 to 12 hours post-dose
Percentage of the Given Dose of Drug Excreted in Urine (fe%) of Gepotidacin
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. fe% was calculated as fe% = (Ae 12 hours/Dose) multiply by 100. The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 and 4: Pre-dose and at 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, and 10 to 12 hours post-dose
Renal Clearance (CLr) of Gepotidacin
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. CLr was calculated as CLr = Ae 12 hours/AUC(0-tau). The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 and 4: Pre-dose and at 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, and 10 to 12 hours post-dose
Urine Pre-dose Concentration (Ctau) of Gepotidacin
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
Time frame: Days 1 to 5: Pre-dose
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious AEs (SAEs)
An AEs is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of gepotidacin.
Time frame: Up to Day 31
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs including SBP and DBP were measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 2, Day 3, Day 4, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Pulse Rate
Vital sign including pulse rate was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 2, Day 3, Day 4, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Body Temperature
Vital sign including body temperature was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 2, Day 3, Day 4, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Bazett's Formula (QTcB) and Corrected QT Interval Using Fridericia's Formula (QTcF)
A 12-lead ECG was measured in semi-supine position using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
Time frame: Baseline; Day 1: 2 hours; Day 4: pre-dose and 2 hours
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet Counts
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet counts. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Hematology Parameter: Hemoglobin
Blood samples were collected to analyze the hematology parameter: Hemoglobin. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: Hematocrit. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: Erythrocyte Mean Corpuscular Hemoglobin. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: Erythrocyte Mean Corpuscular Volume. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Hematology Parameter: Red Blood Cell Count
Blood samples were collected to analyze the hematology parameter: Red blood cell count. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected to analyze the chemistry parameters: Albumin and Protein. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Clinical Chemistry Parameters: Creatinine and Bilirubin
Blood samples were collected to analyze the chemistry parameters: Creatinine and Bilirubin. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (ALP)
Blood samples were collected to analyze the chemistry parameters: ALT, AST and ALP. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Change From Baseline in Clinical Chemistry Parameters: Glucose, Calcium, Chloride, Potassium, Sodium and Urea
Blood samples were collected to analyze the chemistry parameters: Glucose, Calcium, Chloride, Potassium, Sodium and Urea. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Number of Participants With Urinalysis Dipstick Results: Glucose and Nitrites
Urine samples were collected at indicated time points to analyze parameters including glucose and nitrites by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative and positive in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Number of Participants With Urinalysis Dipstick Results: Ketones
Urine samples were collected at indicated time points to analyze parameter including ketones by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, 5 indicates 5 milligrams per deciliter (mg/dL) and 20 indicates 20 mg/dL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase
Urine samples were collected at indicated time points to analyze parameter including leukocyte esterase by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace indicates 15 Leukocytes per microliter (Leuko/mcL), Small indicates 70 Leuko/mcL, Moderate indicates 125 Leuko/mcL and Large indicates 500 Leuko/mcL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Number of Participants With Urinalysis Dipstick Results: Occult Blood
Urine samples were collected at indicated time points to analyze parameter including occult blood by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Small indicates 25 Erythrocytes per microliter (Ery/mcL), Moderate indicates 50 Ery/mcL and Large indicates 250 Ery/mcL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Number of Participants With Urinalysis Dipstick Results: Protein
Urine samples were collected at indicated time points to analyze parameter including protein by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative indicates \<10 mg/dL, 1+ indicates 30 mg/dL and 2+ indicates 100 mg/dL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
Time frame: Baseline, Day 3, Day 5 and Days 10 to 13 (Test-of-cure visit)
Number of Participants With Abnormal Physical Examination Findings
Physical examinations included assessments of the respiratory, cardiovascular, abdominal, gastrointestinal, neurological and urogenital systems. This analysis was planned but data was not collected and captured in the database.
Time frame: Up to Day 31
This was an open-label study to evaluate the pharmacokinetic (PK) of repeat oral doses of gepotidacin in adult female participants with clinical signs and symptoms of acute cystitis.
| Milestone | Gepotidacin 1500 mg |
|---|---|
| Started | 22 |
| Completed | 20 |
| Not completed | 2 |
| Withdrew: Family emergency | 1 |
| Withdrew: Lost to follow-up | 1 |
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. PK Parameter Population consisted of all participants who received gepotidacin 1500 mg BID through the completion of all PK collections for whom valid and evaluable plasma PK parameters were derived for gepotidacin.
| Hours* nanogram per milliliter (h*ng/mL) | Gepotidacin 1500 mg |
|---|---|
| Day 1, n=20 | 20236.2 ± 28.6 |
| Day 4, n=21 | 29313.8 ± 31.8 |
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter (ng/mL) | Gepotidacin 1500 mg |
|---|---|
| Day 1, n=20 | 5891 ± 47.3 |
| Day 4, n=21 | 8437 ± 38.0 |
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
| Hours | Gepotidacin 1500 mg |
|---|---|
| Day 1, n=20 | 1.500 (0.47 to 3.07) |
| Day 4, n=21 | 1.917 (0.45 to 4.12) |
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. CLss/F was calculated as Dose divided by AUC(0-tau).
| Liters per hour | Gepotidacin 1500 mg |
|---|---|
| Apparent Steady State Clearance (CLss/F) of Gepotidacin | 51.17 ± 31.8 |
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Accumulation ratio (Ro) was calculated as ratio of AUC(0-tau) at Day 4 to AUC(0-tau) at Day 1.
| Ratio | Gepotidacin 1500 mg |
|---|---|
| Accumulation Ratio (Ro) of Gepotidacin | 1.402 ± 20.4 |
Blood samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
| ng/mL | Gepotidacin 1500 mg |
|---|---|
| Day 1, Pre-dose, n=22 | NA ± NA |
| Day 2, Pre-dose, n=21 | 620.5 ± 62.3 |
| Day 3, Pre-dose, n=21 | 789.3 ± 37.4 |
| Day 4, Pre-dose, n=21 | 851.4 ± 41.4 |
| Day 5, Pre-dose, n=21 | 818.9 ± 46.4 |
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Ae12hours was calculated by adding all the fractions of drug collected over all the allotted time intervals.
| mg | Gepotidacin 1500 mg |
|---|---|
| Day 1, n=20 | 298.7 ± 107.6 |
| Day 4, n=21 | 460.0 ± 55.8 |
Ae(t1-t2) measure the amount of drug excreted in urine in a time intervals 0 to 2 hours, 2 to 4 hours, 4 to 6 hours, 6 to 8 hours, 8 to 10 hours, and 10 to 12 hours post-dose on Days 1 and 4. The PK parameters were calculated by standard non-compartmental analysis.
| mg | Gepotidacin 1500 mg |
|---|---|
| Day 1, Ae (0-2),n=17 | NA ± NA |
| Day 4, Ae (0-2),n=18 | 63.05 ± 151.7 |
| Day 1, Ae (2-4),n=17 | 131.9 ± 59.5 |
| Day 4, Ae (2-4),n=12 | 168.1 ± 96.5 |
| Day 1, Ae (4-6) ,n=14 | 87.01 ± 90.0 |
| Day 4, Ae (4-6),n=18 | 128.6 ± 96.8 |
| Day 1, Ae (6-8),n=16 | 54.60 ± 72.1 |
| Day 4, Ae (6-8),n=17 | 84.08 ± 92.0 |
| Day 1, Ae (8-10),n=9 | 18.51 ± 49.9 |
| Day 4, Ae (8-10),n=10 | 34.68 ± 69.2 |
| Day 1, Ae (10-12),n=14 | 18.03 ± 151.2 |
| Day 4, Ae (10-12),n=15 | 32.77 ± 83.5 |
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. fe% was calculated as fe% = (Ae 12 hours/Dose) multiply by 100. The PK parameters were calculated by standard non-compartmental analysis.
| Percentage of dose | Gepotidacin 1500 mg |
|---|---|
| Day 1, n=20 | 19.91 ± 107.6 |
| Day 4, n=21 | 30.67 ± 55.8 |
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. CLr was calculated as CLr = Ae 12 hours/AUC(0-tau). The PK parameters were calculated by standard non-compartmental analysis.
| Liters per hour | Gepotidacin 1500 mg |
|---|---|
| Day 1, n=20 | 14.76 ± 118.2 |
| Day 4, n=21 | 15.69 ± 45.2 |
Urine samples were collected to evaluate the PK of gepotidacin at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.
| Micrograms per milliliter | Gepotidacin 1500 mg |
|---|---|
| Day 1, Pre-dose, n=21 | NA ± NA |
| Day 2, Pre-dose, n=20 | 279.1 ± 154.7 |
| Day 3, Pre-dose, n=21 | 322.2 ± 138.8 |
| Day 4, Pre-dose, n=21 | 326.7 ± 248.7 |
| Day 5, Pre-dose, n=21 | 351.7 ± 146.5 |
An AEs is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; and other important medical events which may require medical or surgical intervention. Safety Population consisted of all participants who received at least 1 dose of gepotidacin.
| Participants | Gepotidacin 1500 mg |
|---|---|
| Non-SAEs | 21 |
| SAEs | 1 |
Vital signs including SBP and DBP were measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Millimeters of mercury | Gepotidacin 1500 mg |
|---|---|
| SBP, Day 2,n=22 | -3.1 ± 16.13 |
| SBP, Day 3,n=22 | -0.3 ± 15.74 |
| SBP, Day 4,n=21 | -1.5 ± 13.10 |
| SBP, Day 5,n=21 | 0.9 ± 15.46 |
| SBP, Days 10 to 13,n=20 | 1.5 ± 14.21 |
| DBP, Day 2,n=22 | -2.3 ± 9.32 |
| DBP, Day 3,n=22 | -1.1 ± 11.64 |
| DBP, Day 4,n=21 | 0.5 ± 9.65 |
| DBP, Day 5,n=21 | 4.7 ± 7.23 |
| DBP, Days 10 to 13,n=20 | 2.7 ± 8.77 |
Vital sign including pulse rate was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Beats per minute | Gepotidacin 1500 mg |
|---|---|
| Day 2,n=22 | 2.2 ± 9.07 |
| Day 3,n=22 | 2.4 ± 10.24 |
| Day 4,n=21 | 2.9 ± 12.60 |
| Day 5,n=21 | 7.2 ± 9.50 |
| Days 10 to 13,n=20 | 0.8 ± 12.38 |
Vital sign including body temperature was measured in semi-supine position after 5 minutes of rest for the participants in a quiet setting without distractions. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Degree Celsius | Gepotidacin 1500 mg |
|---|---|
| Day 2,n=22 | -0.05 ± 0.246 |
| Day 3,n=22 | -0.06 ± 0.292 |
| Day 4,n=21 | 0.02 ± 0.405 |
| Day 5,n=21 | -0.05 ± 0.287 |
| Days 10 to 13,n=20 | -0.10 ± 0.270 |
A 12-lead ECG was measured in semi-supine position using an ECG machine that measured PR interval, QRS duration, QT interval, QTcB and QTcF. Baseline was defined as the latest non-missing value at Day -1 or at Day 1 pre-dose. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value.
| Millisecond | Gepotidacin 1500 mg |
|---|---|
| PR interval, Day 1: 2 hours, n=22 | -1.9 ± 11.34 |
| PR interval, Day 4: pre-dose,n=21 | 0.1 ± 14.56 |
| PR interval, Day 4: 2 hours,n=21 | -3.5 ± 10.17 |
| QRS duration, Day 1: 2 hours, n=22 | -0.7 ± 8.32 |
| QRS duration, Day 4: pre-dose,n=21 | -0.9 ± 4.10 |
| QRS duration, Day 4: 2 hours,n=21 | 2.1 ± 4.29 |
| QT interval, Day 1: 2 hours, n=22 | 15.0 ± 21.56 |
| QT interval, Day 4: pre-dose,n=21 | -5.4 ± 26.86 |
| QT interval, Day 4: 2 hours,n=21 | 8.7 ± 27.46 |
| QTcB interval, Day 1: 2 hours, n=22 | 4.5 ± 14.37 |
| QTcB interval, Day 4: pre-dose,n=21 | -6.2 ± 17.25 |
| QTcB interval, Day 4: 2 hours,n=21 | 0.4 ± 27.33 |
| QTcF interval, Day 1: 2 hours, n=22 | 8.2 ± 14.45 |
| QTcF interval, Day 4: pre-dose,n=21 | -5.8 ± 17.57 |
| QTcF interval, Day 4: 2 hours,n=21 | 3.4 ± 24.84 |
Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelet counts. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| 10^9 cells per liter | Gepotidacin 1500 mg |
|---|---|
| Day 3, Basophils, n=16 | 0.013 ± 0.0652 |
| Day 5, Basophils, n=14 | -0.003 ± 0.0164 |
| Days 10 to 13, Basophils, n=15 | 0.000 ± 0.0146 |
| Day 3, Eosinophils, n=18 | 0.013 ± 0.0550 |
| Day 5, Eosinophils, n=17 | -0.003 ± 0.0969 |
| Days 10 to 13, Eosinophils, n=16 | 0.051 ± 0.0492 |
| Day 3, Lymphocytes, n=19 | 0.039 ± 0.5201 |
| Day 5, Lymphocytes, n=18 | 0.041 ± 0.4856 |
| Days 10 to 13, Lymphocytes, n=17 | 0.232 ± 0.4001 |
| Day 3, Monocytes, n=19 | -0.053 ± 0.1080 |
| Day 5, Monocytes, n=18 | -0.069 ± 0.1468 |
| Days 10 to 13, Monocytes, n=17 | -0.039 ± 0.1415 |
| Day 3, Neutrophils, n=19 | -0.673 ± 1.9611 |
| Day 5, Neutrophils, n=18 | -0.948 ± 2.3174 |
| Days 10 to 13, Neutrophils, n=17 | -0.841 ± 1.4779 |
| Day 3, Platelet counts, n=19 | -3.6 ± 22.94 |
| Day 5, Platelet counts, n=18 | 7.8 ± 32.33 |
| Days 10 to 13, Platelet counts, n=17 | 3.7 ± 33.59 |
Blood samples were collected to analyze the hematology parameter: Hemoglobin. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Grams per liter | Gepotidacin 1500 mg |
|---|---|
| Day 3, n=19 | -3.4 ± 8.15 |
| Day 5, n=18 | -0.6 ± 9.34 |
| Days 10 to 13, n=17 | -8.2 ± 7.40 |
Blood samples were collected to analyze the hematology parameter: Hematocrit. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Percentage of red blood cells in blood | Gepotidacin 1500 mg |
|---|---|
| Day 3, n=19 | 0.75 ± 3.186 |
| Day 5, n=18 | -0.54 ± 3.643 |
| Days 10 to 13, n=17 | -2.30 ± 2.956 |
Blood samples were collected to analyze the hematology parameter: Erythrocyte Mean Corpuscular Hemoglobin. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Picogram | Gepotidacin 1500 mg |
|---|---|
| Day 3, n=19 | 0.13 ± 0.564 |
| Day 5, n=18 | 0.03 ± 0.465 |
| Days 10 to 13, n=17 | 0.16 ± 0.348 |
Blood samples were collected to analyze the hematology parameter: Erythrocyte Mean Corpuscular Volume. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Femtoliter | Gepotidacin 1500 mg |
|---|---|
| Day 3, n=19 | 4.53 ± 5.814 |
| Day 5, n=18 | -0.72 ± 4.668 |
| Days 10 to 13, n=17 | 1.14 ± 6.252 |
Blood samples were collected to analyze the hematology parameter: Red blood cell count. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| 10^12 cells per liter | Gepotidacin 1500 mg |
|---|---|
| Day 3, n=19 | -0.135 ± 0.2574 |
| Day 5, n=18 | -0.031 ± 0.3060 |
| Days 10 to 13, n=17 | -0.298 ± 0.2552 |
Blood samples were collected to analyze the chemistry parameters: Albumin and Protein. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Grams per liter | Gepotidacin 1500 mg |
|---|---|
| Albumin: Day 3, n=22 | -2.0 ± 2.45 |
| Albumin: Day 5, n=21 | -1.4 ± 2.71 |
| Albumin: Days 10 to 13, n=20 | -1.3 ± 2.90 |
| Protein: Day 3, n=22 | -3.0 ± 3.82 |
| Protein: Day 5, n=21 | -2.6 ± 4.52 |
| Protein: Days 10 to 13, n=20 | -2.4 ± 5.13 |
Blood samples were collected to analyze the chemistry parameters: Creatinine and Bilirubin. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Micromoles per liter | Gepotidacin 1500 mg |
|---|---|
| Creatinine: Day 3, n=22 | 2.411 ± 9.9048 |
| Creatinine: Day 5, n=21 | 1.684 ± 7.7162 |
| Creatinine: Days 10 to 13, n=20 | 0.442 ± 7.2981 |
| Bilirubin: Day 3, n=14 | -1.8932 ± 4.06405 |
| Bilirubin: Day 5, n=15 | -1.6986 ± 3.41356 |
| Bilirubin: Days 10 to 13, n=14 | -1.6856 ± 3.42845 |
Blood samples were collected to analyze the chemistry parameters: ALT, AST and ALP. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| International units per liter | Gepotidacin 1500 mg |
|---|---|
| ALT: Day 3, n=22 | -1.5 ± 4.99 |
| ALT: Day 5, n=21 | 1.7 ± 7.51 |
| ALT: Days 10 to 13, n=20 | 1.7 ± 7.44 |
| AST: Day 3, n=22 | -1.3 ± 3.22 |
| AST: Day 5, n=21 | 1.3 ± 3.77 |
| AST: Days 10 to 13, n=20 | 2.1 ± 3.22 |
| ALP: Day 3, n=22 | -3.3 ± 7.91 |
| ALP: Day 5, n=21 | -4.3 ± 8.84 |
| ALP: Days 10 to 13, n=20 | -4.5 ± 7.76 |
Blood samples were collected to analyze the chemistry parameters: Glucose, Calcium, Chloride, Potassium, Sodium and Urea. Baseline was defined as Day -1. Change from Baseline was calculated by subtracting the post-dose visit value from the Baseline value. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13.
| Millimoles per liter | Gepotidacin 1500 mg |
|---|---|
| Day 3, Glucose, n=22 | 0.13121 ± 1.237031 |
| Day 5, Glucose, n=21 | 0.87495 ± 1.382514 |
| Days 10 to 13, Glucose, n=20 | -0.05274 ± 0.498607 |
| Day 3, Calcium, n=22 | -0.05330 ± 0.075175 |
| Day 5, Calcium, n=21 | -0.05228 ± 0.093648 |
| Days 10 to 13, Calcium, n=20 | -0.07110 ± 0.095536 |
| Day 3, Chloride, n=22 | 0.5 ± 2.42 |
| Day 5, Chloride, n=21 | 0.3 ± 2.90 |
| Days 10 to 13, Chloride, n=20 | 0.3 ± 2.15 |
| Day 3, Potassium, n=22 | 0.04 ± 0.359 |
| Day 5, Potassium, n=21 | -0.05 ± 0.425 |
| Days 10 to 13, Potassium, n=20 | 0.01 ± 0.419 |
| Day 3, Sodium, n=22 | -0.7 ± 2.29 |
| Day 5, Sodium, n=21 | -1.6 ± 2.13 |
| Days 10 to 13, Sodium, n=20 | -0.9 ± 1.65 |
| Day 3, Urea, n=22 | 0.1298 ± 1.15836 |
| Day 5, Urea, n=21 | 0.0680 ± 1.06275 |
| Days 10 to 13, Urea, n=20 | 0.3927 ± 1.18063 |
Urine samples were collected at indicated time points to analyze parameters including glucose and nitrites by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative and positive in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
| Participants | Gepotidacin 1500 mg |
|---|---|
| Baseline:Glucose,Negative,n=22 | 22 |
| Day 3:Glucose,Negative,n=22 | 22 |
| Day 5:Glucose,Negative,n=21 | 21 |
| Days 10 to 13:Glucose,Negative,n=20 | 20 |
| Baseline: Nitrites,Negative,n=22 | 13 |
| Baseline: Nitrites,Positive,n=22 | 9 |
| Day 3: Nitrites,Negative,n=22 | 22 |
| Day 5: Nitrites,Negative,n=21 | 21 |
| Days 10 to 13: Nitrites,Negative,n=20 | 20 |
Urine samples were collected at indicated time points to analyze parameter including ketones by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, 5 indicates 5 milligrams per deciliter (mg/dL) and 20 indicates 20 mg/dL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
| Participants | Gepotidacin 1500 mg |
|---|---|
| Baseline:Ketones,Negative,n=22 | 21 |
| Baseline:Ketones,20,n=22 | 1 |
| Day 3:Ketones,Negative,n=22 | 22 |
| Day 5:Ketones,Negative,n=21 | 21 |
| Days 10 to 13:Ketones,Negative,n=20 | 18 |
| Days 10 to 13:Ketones,5,n=20 | 2 |
Urine samples were collected at indicated time points to analyze parameter including leukocyte esterase by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Trace indicates 15 Leukocytes per microliter (Leuko/mcL), Small indicates 70 Leuko/mcL, Moderate indicates 125 Leuko/mcL and Large indicates 500 Leuko/mcL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
| Participants | Gepotidacin 1500 mg |
|---|---|
| Baseline:Leukocyte esterase,Negative,n=22 | 4 |
| Baseline:Leukocyte esterase,Trace,n=22 | 2 |
| Baseline:Leukocyte esterase,Small,n=22 | 4 |
| Baseline:Leukocyte esterase,Moderate,n=22 | 1 |
| Baseline:Leukocyte esterase,Large,n=22 | 11 |
| Day 3:Leukocyte esterase,Negative,n=22 | 19 |
| Day 3:Leukocyte esterase,Small,n=22 | 1 |
| Day 3:Leukocyte esterase,Moderate,n=22 | 2 |
| Day 5:Leukocyte esterase,Negative,n=21 | 16 |
| Day 5:Leukocyte esterase,Trace,n=21 | 4 |
| Day 5:Leukocyte esterase,Small,n=21 | 1 |
| Days 10 to 13:Leukocyte esterase,Negative,n=20 | 19 |
| Days 10 to 13:Leukocyte esterase,Trace,n=20 | 1 |
Urine samples were collected at indicated time points to analyze parameter including occult blood by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, Small indicates 25 Erythrocytes per microliter (Ery/mcL), Moderate indicates 50 Ery/mcL and Large indicates 250 Ery/mcL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
| Participants | Gepotidacin 1500 mg |
|---|---|
| Baseline:Occult blood,Negative,n=22 | 6 |
| Baseline:Occult blood,Small,n=22 | 10 |
| Baseline:Occult blood,Moderate,n=22 | 3 |
| Baseline:Occult blood,Large,n=22 | 3 |
| Day 3:Occult blood,Negative,n=22 | 19 |
| Day 3:Occult blood,Small,n=22 | 1 |
| Day 3:Occult blood,Moderate,n=22 | 1 |
| Day 3:Occult blood,Large,n=22 | 1 |
| Day 5:Occult blood,Negative,n=21 | 17 |
| Day 5:Occult blood,Small,n=21 | 2 |
| Day 5:Occult blood,Moderate,n=21 | 2 |
| Days 10 to 13:Occult blood,Negative,n=20 | 18 |
| Days 10 to 13:Occult blood,Small,n=20 | 2 |
Urine samples were collected at indicated time points to analyze parameter including protein by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative indicates \<10 mg/dL, 1+ indicates 30 mg/dL and 2+ indicates 100 mg/dL in the urine sample. Baseline was defined as Day -1. Assessment at Test-of-cure visit was conducted between any day of Days 10 to 13. Only categories with significant values have been presented.
| Participants | Gepotidacin 1500 mg |
|---|---|
| Baseline: Protein,Negative,n=22 | 11 |
| Baseline: Protein,1+,n=22 | 10 |
| Baseline: Protein,2+,n=22 | 1 |
| Day 3: Protein,Negative,n=22 | 18 |
| Day 3: Protein,1+,n=22 | 4 |
| Day 5: Protein,Negative,n=21 | 16 |
| Day 5: Protein,1+,n=21 | 5 |
| Days 10 to 13: Protein,Negative,n=20 | 18 |
| Days 10 to 13: Protein,1+,n=20 | 2 |
Physical examinations included assessments of the respiratory, cardiovascular, abdominal, gastrointestinal, neurological and urogenital systems. This analysis was planned but data was not collected and captured in the database.
No measurements were reported for this outcome.
Collected over Non-SAEs and SAEs were collected from start of the treatment (Day 1) up to Day 31. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gepotidacin 1500 mg | 0/22 (0%) | 1/22 (4.5%) | 21/22 (95.5%) |
| Event | Gepotidacin 1500 mg |
|---|---|
| Major depressionPsychiatric disorders | 1/22 |
| Event | Gepotidacin 1500 mg |
|---|---|
| DiarrhoeaGastrointestinal disorders | 18/22 |
| NauseaGastrointestinal disorders | 17/22 |
| VomitingGastrointestinal disorders | 5/22 |
| HeadacheNervous system disorders | 5/22 |
| Viral upper respiratory tract infectionInfections and infestations | 2/22 |
| Vulvovaginal mycotic infectionInfections and infestations | 2/22 |
| Back painMusculoskeletal and connective tissue disorders | 2/22 |
| Chest discomfortGeneral disorders | 2/22 |
| Age, Continuous(Years) | Gepotidacin 1500 mg |
|---|---|
| Mean | 37.1 ± 12.26 |
| Sex: Female, Male(Participants) | Gepotidacin 1500 mg |
|---|---|
| Female | 22 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Gepotidacin 1500 mg |
|---|---|
| Black or African American | 4 |
| White - White/Caucasian/European Heritage | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jul 2018 to primary completion in Jan 2019, 5 months.
Results were first posted in Jan 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin